Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1482-1490

  Sakamoto, K ^a   Mikami, H ^a   Kimura, J ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Drug transporters; Organic anion transporting polypeptide; Rhabdomyolysis; Skeletal muscle; Statins

Indexed keywords

ESTRONE SULFATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FIBROBLAST; HYDROPHILICITY; LIPOPHILICITY; MUSCLE FIBRIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOLYSIS; SATELLITE CELL; TOXICITY TESTING;

ANIMALS; CELL DEATH; CELL LINE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FIBROBLASTS; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS; ORGANIC ANION TRANSPORTERS; PRAVASTATIN; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 48149093606     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.192     Document Type: Article

References (49)

1. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M et al. (1998). Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem 273: 22395-22401.
2. Allen RE, Temm-Grove CJ, Sheehan SM, Rice G (1997). Skeletal muscle satellite cell cultures. Method Cell Biol 52: 155-176.
3. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH (2005). The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111: 3051-3057.
4. Anzai N, Kanai Y, Endou H (2006). Organic anion transporter family: current knowledge. J Pharmacol Sci 100: 411-426.
5. Bischoff R (1986). Proliferation of muscle satellite cells on intact myofibers in culture. Dev Biol 115: 129-139.
6. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B (2005). Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19: 403-414.
7. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T et al. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286.
8. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM (2001). Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 68: 430-433.
9. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
10. Endo A (1992). The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33: 1569-1582.
11. Fichtl B, Kurz H (1978). Binding of drugs to human muscle. Eur J Clin Pharmacol 14: 335-340.
12. Gao B, Wenzel A, Grimm C, Vavricka SR, Benke D, Meier PJ et al. (2002). Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 43: 510-514.
13. Goldberg R, Roth D (1996). Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 62: 1559-1564.
14. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L et al. (2006). Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80: 607-620.
15. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H et al. (2002). Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 300: 746-753.
16. Holdgate GA, Ward WH, McTaggart F (2003). Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31: 528-531.
17. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP et al. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274: 37161-37168.
18. Ichihara K, Satoh K (2002). Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 359: 2195-2198.
19. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S (2006). Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63: 2415-2425.
20. Kivisto KT, Kantola T, Neuvonen PJ (1998). Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46: 49-53.
21. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2003). Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306: 703-708.
22. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y (1992). Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209: 315-319.
23. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH et al. (1999). Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274: 13675-13680.
24. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ (2004). Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 57: 181-187.
25. Marie I, Delafenêtre H, Massy N, Thuillez C, Noblet C, Network of the French Pharmacovigilance Centers (2008). Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 59: 367-372.
26. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK (1995). In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131: 163-174.
27. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D et al. (2001). Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87: 28B-32B.
28. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T (2004). The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19: 171-179.
29. 2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 202: 1579-1585.
30. Nishimura M, Naito S (2005). Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20: 452-477.
31. Noe J, Portmann R, Brun ME, Funk C (2007). Substrate dependent drug-drug interactions between gemfibrozil, fluvastatin and other OATP substrates on OATP1B1, OATP2B1 and OATP1B3. Drug Metab Dispos 35: 1308-1314.
32. Ohkubo S, Kimura J, Matsuoka I (2000). Ecto-alkaline phosphatase in NG108-15 cells: a key enzyme mediating P1 antagonist-sensitive ATP response. Br J Pharmacol 131: 1667-1672.
33. Ohtsuki S, Takizawa T, Takanaga H, Terasaki N, Kitazawa T, Sasaki M et al. (2003). In vitro study of the functional expression of organic anion transporting polypeptide 3 at rat choroid plexus epithelial cells and its involvement in the cerebrospinal fluid-to-blood transport of estrone-3-sulfate. Mol Pharmacol 63: 532-537.
34. Regazzi MB, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G (1994). Altered disposition of pravastatin following comcominant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 26: 2644-2645.
35. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J (2007). Rabsmall GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J 21: 4087-4094.
36. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y (2004). Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66: 450-459.
37. Serrano MA, Macias RI, Vallejo M, Briz O, Bravo A, Pascual MJ et al. (2003). Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J Pharmacol Exp Ther 305: 515-524.
38. Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H, Sugiyama Y (2004). In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug Metab Dispos 32: 1468-1475.
39. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304: 610-616.
40. Shitara Y, Sugiyama Y (2006). Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71-105.
41. Sirtori CR (1993). Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther 60: 431-459.
42. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE (1995). Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76: 80A-83A.
43. Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H et al. (2003). The blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem 278: 43489-43495.
44. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang XL et al. (2004). Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 483: 133-138.
45. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y (1999). Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16: 904-908.
46. Ucar M, Mjorndal T, Dahlqvist R (2000). HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22: 441-457.
47. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H et al. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
48. Yaffe D (1968). Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 61: 477-483.
49. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y (1997). Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25: 1123-1129.